期刊
LUNG CANCER
卷 123, 期 -, 页码 44-51出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2018.06.027
关键词
Plasma microRNA; Lung cancer; Early diagnosis; Subtype discrimination
资金
- National Key Sci-Tech Support Program of China [2013BAI09B09]
- 973 Program of the Ministry of Sci-Tech of China [2012CB933304]
- National Key Technology R&D Program of the 12th National Five-year Development Plan [2012BAI05B01]
- National Natural Science Foundation of China [81472174, 81401879]
- Sci-Tech Commission of Shanghai Municipality [14ZR1406100]
- Medical Guide Project of Science and Technology Commission of Shanghai Municipality [14411965900]
- Key Developing Discipline [2015ZB0201]
Objectives: Early and accurate diagnosis of lung cancer is crucial for effective treatment. This study aimed to identify plasma microRNAs for diagnosis of lung cancer and for further discrimination of small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC). Materials and methods: Plasma microRNA expression was investigated using three independent cohorts including 1132 participants recruited between October 2008 and September 2014 from five medical centers. The subjects were healthy individuals and patients with NSCLC or SCLC. Microarrays were used to screen 723 human microRNAs in 106 plasma samples for candidate selection. Quantitative reverse-transcriptase PCR was applied to evaluate the expression of selected microRNAs. Two logistic regression models were constructed based on a training cohort (n = 565) and then validated using an independent cohort (n = 461). The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy. Results: Plasma panel A with six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals (AUC 0.873 and 0.868 for training and validation cohort, respectively). Moreover, plasma panel B with three microRNAs (miR-17, miR-190b, and miR-375) demonstrated high diagnostic accuracy in discriminating SCLC from NSCLC (AUC 0.878 and 0.869 for training and validation cohort, respectively). Conclusion: We constructed and validated two plasma microRNA panels that have considerable clinical value in diagnosis of lung cancer, and could play an important role in determining optimal treatment strategies based on discrimination between SCLC and NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据